The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France
References (45)
Diagnosis of osteoporosis and assessment of fracture risk
Lancet
(2002)Compliance with treatment regimens in chronic asymptomatic diseases
Am J Med
(1997)- et al.
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
Lancet
(1996) - et al.
Compliance with drug therapies for the treatment and prevention of osteoporosis
Maturitas
(2004) - et al.
Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women
- et al.
Patient preference for once weekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, openlabel, crossover study
Clin Ther
(2002) - et al.
Patients with osteoporosis prefer once weekly to once daily dosing with alendronate
Maturitas
(2004) - et al.
Predictors of long-term persistence on statins in a subsidized clinical population
Value Health
(2000) - et al.
A systematic review of the associations between dose regimens and medication compliance
Clin Ther
(2001) - et al.
Adherence to bisphosphonate ther apy and fracture rates in osteoporotic women: Relationship to vertebral and nonvetebral fractures from 2 US claims databases
Medication compliance feedback and monitoring in a clinical trial: Predictors and outcomes
Value Health
(2003)
The use of claims databases for outcomes research: Rationale, challenges, and strategies
Clin Ther
(1997)
Vertebral fracture and cortical bone changes in corticosteroid-induced osteoporosis
Osteoporos Int
(2002)
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis
Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Fou ndation
J Bone Miner Res
(1997)
America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation
(2002)
Requirements for DXA for the management of osteoporosis in Europe
Osteoporos Int
(2005)
Long-term persistence in use of statin therapy in elderly patients
JAMA
(2002)
Assessing compliance to antihypertensive medications usingcomputerbased pharmacy records
Med Care
(1997)
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
JAMA
(1999)
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial
J Clin Endocrinol Metab
(2002)
Effects of oral iban dronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
J Bone Miner Res
(2004)
Cited by (98)
Utilization outcomes of direct oral anticoagulants in Medicare patients
2023, Research in Social and Administrative PharmacyCondition still critical: Compliance and persistence with osteoporosis medications
2020, Marcus and Feldman’s OsteoporosisChanges in medication adherence and unused drugs after switching from daily dipeptidyl peptidase-4 inhibitors to once-weekly trelagliptin in patients with type 2 diabetes
2019, Diabetes Research and Clinical PracticeManagement of Rheumatology Disorders and the Pharmacist's Role: Osteoporosis
2019, Encyclopedia of Pharmacy Practice and Clinical Pharmacy: Volumes 1-3Management of rheumatology disorders and the pharmacist’s role: Osteoporosis
2019, Encyclopedia of Pharmacy Practice and Clinical PharmacyDenosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study
2018, The Lancet Diabetes and Endocrinology
Copyright © 2006 Published by Elsevier Inc.